Avastin® Herceptin® Breast cancer HER 2+ About Herceptin® Herceptin® development Administration Efficacy Adjunvant efficacy HERA Trial NCCTG N9831 Trial NSABP B-31 Trial BCIRG 006 Trial Neoadjuvant efficacy Metastasic breast cancer efficacy Safety Cardiac safety Dosage Mabthera® Tarceva® Xeloda®

Home/EN/Product information/Herceptin®/Efficacy/Adjunvant efficacy/HERA Trial HERA Trial  A non-US, Phase III, randomised, multicentre, open-label trial comparing adjuvant Herceptin® for 1 or 2 years versus observation only in HER2-positive EBC.

Privacy Policy | Legal Statement The information on this Web site is intended only for visitors from Aruba, Bahamas, Barbados, Bermuda, Curacao, Jamaica, St. Maarten, St. Lucia and Trinidad & Tobago All rights reserved © 2008 F. Hoffmann-La Roche Ltd.